Kisqali, a targeted therapy for breast cancer developed by Novartis, has received a significant approval from the Food and Drug Administration (FDA). Previously indicated only for patients with metastatic disease, Kisqali is now approved in combination with hormone therapy for patients with certain early-stage breast cancers. This expansion of approval will allow a larger number of patients to access this important drug.
Victor Bulto, president of Novartis United States unit, highlighted the significance of this approval, stating that it includes the entire stage 3 and 70% of stage 2 breast cancer patients. This approval sets Kisqali apart from other CDK4/6 inhibitors, as it now offers treatment to patients who do not have positive lymph nodes. CDK4/6 inhibitors like Kisqali target proteins that can enable cancer cells to grow uncontrollably, making them a key part of treatment for advanced hormone receptor positive, HER2 negative breast cancer.
The approval of Kisqali in early-stage breast cancer expands the options available to patients who may not have been considered candidates for other CDK4/6 inhibitors. Patients will receive Kisqali with endocrine therapy for three years after surgery to reduce the risk of recurrence. Data from Novartis’ Phase 3 NATALEE trial presented at the European Society of Medical Oncology meeting showed that Kisqali can reduce the risk of recurrence by 28.5% compared to endocrine therapy alone.
While Kisqali offers promising benefits, it does come with some side effects, including low white blood cell counts and joint pain. However, the benefits of treatment outweigh the risks for many patients. It is important to note that early detection of breast cancer is crucial, as cancers at earlier stages can often be effectively treated without the need for CDK4/6 inhibitors or chemotherapy.
The approval of Kisqali for early-stage breast cancer marks a significant advancement in the treatment options available to patients. This new approval opens up the possibility of using CDK4/6 inhibitors in a broader group of patients, further improving outcomes and quality of life for those affected by breast cancer. Novartis continues to lead the way in developing innovative treatments for breast cancer, providing hope and progress for patients and healthcare providers alike.
